Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive information associated with identifying a first transmit power for a first carrier in a band and a second transmit power for a second carrier in the band, wherein the first transmit power and the second transmit power exceed a per-carrier group power threshold. The UE may transmit at least one of a first communication using a first scaled transmit power or a second communication using a second scaled transmit power, wherein at least one of the first transmit power or the second transmit power is scaled to form the first scaled transmit power or the second scaled transmit power in connection with the per-carrier group power threshold. Numerous other aspects are described.

Abstract: One example includes a computer system. Ports each receive signals corresponding to an interface input associated with user physical interaction provided via an interface device in one of disparate input modes. A multi-modal input system maps an interface input associated with one of the ports provided in a given one of the disparate input modes into a computer input command, maps an interface input associated with another of the ports provided in another one of the disparate input modes into another computer input command, and aggregates the computer input commands into a multi-modal event command. A processor executes a single predetermined function associated with the computer system in response to the multi-modal event command. Thus, the processor is configured to execute the single predetermined function associated with the computer system in response to user physical interaction provided in at least two of the plurality of disparate input modes.

Abstract: The present invention is a system and method for arranging duty with transport among parties, which method includes the steps of: enabling a customer at a first geographic location to access a database of a main service in order to select a duty and make a request for the duty, selecting a respondent at a second geographic location from a respondent pool of candidate respondents of the duty, communicating a progress information that contains the second geographic location to the customer, giving pay to the respondents after the respondents finished the duty for the customer, and collecting a first feedback from the customer and a second feedback from the respondents regarding the other party in the transaction.

Abstract: A stethoscope cover having an enclosure with a closed end and an open end. An arrangement (e.g., a circular element) can be located substantially near the closed end can hold a bell of the stethoscope. A V-shaped elastic arrangement can be located at the open end and can extend the enclosure when earpieces of a stethoscope can be pulled apart. A strap can be located at the open and can hold the stethoscope in the enclosure.

Abstract: A cardio electrotherapy lead is disclosed herein. In one embodiment, the lead includes a tubular body, a conductor cable and an electrode. The conductor cable longitudinally extends through the tubular body and includes a distal end. The electrode is located on the tubular body and includes an attachment mechanism mechanically coupling the lead distal end to the electrode.

Abstract: A composite lead body includes a rigid polymer material, such as silicone-polyurethane co-polymers, in a proximal portion of the lead body and a flexible polymer material, such as silicone, in a distal portion of the lead body. The flexible polymer material is molded in-situ about the end of the rigid polymer material, which is pre-formed, forming a junction at which the two polymers are bonded together, preferably in an interdigitated manner. The end of the rigid polymer is treated with a primer in order to facilitate the formation of a strong bond between the polymers. The molding process, advantageously, provides substantial control over the final shape of the molded polymer, inhibiting the formation of discontinuities in the shape of the lead body.

Abstract: A cardio electrotherapy lead is disclosed herein. In one embodiment, the lead includes a tubular body, a conductor cable and an electrode. The conductor cable longitudinally extends through the tubular body and includes a distal end. The electrode is located on the tubular body and includes an attachment mechanism mechanically coupling the lead distal end to the electrode.

Abstract: A cardio electrotherapy lead is disclosed herein. In one embodiment, the lead includes a tubular body, a conductor cable and an electrode. The conductor cable longitudinally extends through the tubular body and includes a distal end. The electrode is located on the tubular body and includes an attachment mechanism mechanically coupling the lead distal end to the electrode.

Abstract: Polymeric delivery devices have been developed which combine high loading/high density of molecules to be delivered with the option of targeting. As used herein, “high density” refers to microparticles having a high density of ligands or coupling agents, which is in the range of 1000-10,000,000, more preferably between 10,000 and 1,000,000 ligands per square micron of microparticle surface area. A general method for incorporating molecules into the surface of biocompatible polymers using materials with an HLB of less than 10, more preferably less than 5, such as fatty acids, has been developed. Because of its ease, generality and flexibility, this method has widespread utility in modifying the surface of polymeric materials for applications in drug delivery and tissue engineering, as well other fields.

Abstract: Polymeric microparticles have been developed which encapsulate therapeutic compounds such as drugs, cellular materials or components, and antigens, and can have targeting ligands directly bound to the microparticle surface. Preferred applications include use in tissue engineering matrices, wound dressings, bone repair or regeneration materials, and other applications where the microparticles are retained at the site of application or implantation. Another preferred application is in the use of microparticles to deliver anti-proliferative agents to the lining of blood vessels following angioplasty, transplantation or bypass surgery to prevent or decrease restenosis, and in cancer therapy. In still another application, the microparticles are used to treat or prevent macular degeneration when administered to the eye, where agents such as complement inhibitors are administered.

Abstract: Polymeric microparticles have been developed which encapsulate therapeutic compounds such as drugs, cellular materials or components, and antigens, and can have targeting ligands directly bound to the microparticle surface. Preferred applications include use in tissue engineering matrices, wound dressings, hone repair or regeneration materials, and other applications where the microparticles are retained at the site of application or implantation. Another preferred application is in the use of microparticles to deliver anti-proliferative agents to the lining of blood vessels following angioplasty, transplantation or bypass surgery to prevent or decrease restenosis, and in cancer therapy. In still another application, the microparticles are used to treat or prevent macular degeneration when administered to the eye, where agents such as complement inhibitors are administered.

Abstract: Polymeric microparticles have been developed which encapsulate therapeutic compounds such as drugs, cellular materials or components, and antigens, and can have targeting ligands directly bound to the microparticle surface. Preferred applications include use in tissue engineering matrices, wound dressings, bone repair or regeneration materials, and other applications where the microparticles are retained at the site of application or implantation. Another preferred application is in the use of microparticles to deliver anti-proliferative agents to the lining of blood vessels following angioplasty, transplantation or bypass surgery to prevent or decrease restenosis, and in cancer therapy. In still another application, the microparticles are used to treat or prevent macular degeneration when administered to the eye, where agents such as complement inhibitors are administered.

Abstract: Polymeric delivery devices have been developed which combine high loading/high density of molecules to be delivered with the option of targeting. As used herein, “high density” refers to microparticles having a high density of ligands or coupling agents, which is in the range of 1000-10,000,000, more preferably between 10,000 and 1,000,000 ligands per square micron of microparticle surface area. A general method for incorporating molecules into the surface of biocompatible polymers using materials with an HLB of less than 10, more preferably less than 5, such as fatty acids, has been developed. Because of its ease, generality and flexibility, this method has widespread utility in modifying the surface of polymeric materials for applications in drug delivery and tissue engineering, as well other other fields.

Abstract: Polymeric microparticles have been developed which encapsulate therapeutic compounds such as drugs, cellular materials or components, and antigens, and can have targeting ligands directly bound to the microparticle surface. Preferred applications include use in tissue engineering matrices, wound dressings, hone repair or regeneration materials, and other applications where the microparticles are retained at the site of application or implantation. Another preferred application is in the use of microparticles to deliver anti-proliferative agents to the lining of blood vessels following angioplasty, transplantation or bypass surgery to prevent or decrease restenosis, and in cancer therapy. In still another application, the microparticles are used to treat or prevent macular degeneration when administered to the eye, where agents such as complement inhibitors are administered.